Eli Lilly
FibroGen CEO Conterno Resigns Amid Roxadustat Launch Setbacks
Source – FibroGen Enrique Conterno, who became FibroGen’s CEO in early 2020, had high hopes for the anemia drug roxadustat ...
Medicare prescription coverage for obesity is supported by legislation by Novo Nordisk, Eli Lilly, and Boehringer Ingelheim
Despite the considerable excitement surrounding the potential of new and potent obesity medicines, these drugs remain inaccessible to many Americans ...
Donanemab Shows Significant Advance in Alzheimer’s Treatment
Source – Eli Lilly The full data from Eli Lilly’s TRAILBLAZER-ALZ 2 trial of the amyloid drug donanemab has validated ...
Lilly’s Acquisition of Versanis Aims to Enhance Patient Outcomes in Cardiometabolic Diseases
Source – Eli Lilly Eli Lilly and Versanis Bio have reached a definitive agreement for Lilly to acquire Versanis, a ...
Pirtobrutinib Shows Promise as a Novel CLL/SLL Treatment for Patients Previously Treated with BTK Inhibitors
Source – Eli Lilly On July 6, 2023, Eli Lilly and Company’s oncology unit announced that The New England Journal ...
Sigilon Therapeutics will be acquired by Lilly
Source – Eli Lilly On June 29, 2023 Eli Lilly and Company and Sigilon Therapeutics entered into a definitive agreement, ...
National Institute for Health and Care Excellence remains skeptical about the effectiveness of Mounjaro for diabetes
Eli Lilly has received positive data for its experimental obesity therapies, but in the UK, it faced a setback as ...
Eli Lilly agrees to pay $2.4 million to resolve an age discrimination lawsuit filed by a federal agency
Eli Lilly has settled a significant lawsuit related to age discrimination allegations. The company will pay $2.4 million as part ...
Novo Nordisk and Eli Lilly Drive Breakthroughs in Oral GLP-1 Treatments for Obesity at ADA Conference
Novo Nordisk and Eli Lilly showcased advancements in the development of oral GLP-1 treatments for Type II diabetes and obesity ...
Lilly’s Retatrutide Shows Promising Phase II Results By Weight Reduction in Adults with Obesity and Overweight
Source – Eli Lilly On June 26, 2023, Eli Lilly and Company announced the release of new Phase II findings ...
Lilly’s SURMOUNT-2 Study Shows Tirzepatide Achieves Significant 15.7% Weight Reduction in Adults with Obesity and Type 2 Diabetes
Source – Eli Lilly On June 24, 2023, Eli Lilly and Company’s tirzepatide showed promising results in the SURMOUNT-2 Phase ...
Lilly’s Orforglipron Shows Promising Weight Reduction in Obesity and Overweight Patients: Phase II Findings
Source – Eli Lilly On June 23, 2023, Eli Lilly and Company announced the Phase II results for orforglipron, an ...
EU Drug Regulator Scrutinizes Novo Nordisk and Eli Lilly Over GLP-1 Safety
The increased inspection of GLP-I therapies by the European Medicines Agency (EMA) has raised a warning about the possibility that ...
In a migraine head-to-head matchup, Pfizer’s Nurtec defeats Eli Lilly’s Emgality
Source – PR Newswire In a side-by-side comparison, Emgality did not outperform Pfizer’s Nurtec in preventing episodic migraines, Lilly said ...
DICE Therapeutics will be acquired by Lilly in order to advance immunology innovation
Source – Eli Lilly On June 20, 2023 a formal deal for Lilly to purchase DICE was announced by Eli ...
Lilly Launches “Tap the Cap” with Adam Duvall, the American Diabetes Association, and other partners
Source – Eli Lilly 20 June 2023, together with the American Diabetes Association (ADA) and professional baseball player Adam Duvall, ...
At the 83rd Scientific Sessions of the American Diabetes Association, Lilly will discuss fresh findings in the management of diabetes and obesity
Source – Eli Lilly On 20 June 2023 at the American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego ...
The US FDA has approved the use of Jardiance (empagliflozin) to treat type II diabetes in children and adolescents aged 10 and older
Source – Eli Lilly On June 21, 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the US Food ...
Weight-Loss Medications Market Projected to Reach $60 Billion in 10 Years
According to a Morningstar analyst, frantic demand for pharmaceuticals to treat obesity from Novo Nordisk, Eli Lilly, and other companies ...
